Exogenous/Endogenous-Triggered Mesoporous Silica Cancer Nanomedicine.

Abstract

Recent advances in nanomedicine-based theranostic platforms have catalyzed the generation of new theranostic modalities for pathological abnormalities, such as cancer. Mesoporous silica-based nanomedicines, which feature unique physicochemical properties and specific applicability, are extensively explored for numerous oncological applications. Due to the well-defined morphology, specific surface area, and pore volume, mesoporous silica nanoparticle (MSN)-based theranostic platforms have provided unprecedented opportunities for the development of next-generation cancer nanomedicine. However, current understanding on the underlying mechanisms of how these feasible theranostic platforms interact with exogenous/endogenous triggers and how this unique responsiveness for optimized cancer therapy can be taken advantage of is still preliminary. In this progress report, efforts are made to give a comprehensive overview of the development of MSN-based "smart" theranostic platforms, from exogenous physical irradiation-triggered platforms for localized therapy to endogenous biological stimulus-triggered platforms for tumor microenvironment responsiveness. It is highly expected that these elaborately fabricated MSN-based nanoformulations will play an indispensable role in the efficient cancer therapy based on their high therapeutic outcome and reduced side effects.